Solid Biosciences Inc. (SLDB)
Automate Your Wheel Strategy on SLDB
With Tiblio's Option Bot, you can configure your own wheel strategy including SLDB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLDB
- Rev/Share 0.0
- Book/Share 7.2143
- PB 0.6446
- Debt/Equity 0.0802
- CurrentRatio 10.8902
- ROIC -0.4484
- MktCap 360446610.0
- FreeCF/Share -2.6289
- PFCF -3.3592
- PE -1.3588
- Debt/Assets 0.0687
- DivYield 0
- ROE -0.7055
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SLDB | Truist | -- | Buy | -- | $16 | Jan. 8, 2025 |
| Initiation | SLDB | Wedbush | -- | Outperform | -- | $16 | Dec. 13, 2024 |
| Initiation | SLDB | JMP Securities | -- | Mkt Outperform | -- | $15 | Dec. 10, 2024 |
News
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees.
Read More
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
Read More
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Published: February 19, 2025 by: MarketBeat
Sentiment: Positive
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
Read More
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Published: February 18, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Read More
Solid Biosciences Announces Pricing of Underwritten Offering
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions …
Read More
About Solid Biosciences Inc. (SLDB)
- IPO Date 2018-01-26
- Website https://www.solidbio.com
- Industry Biotechnology
- CEO Mr. Alexander G. Cumbo
- Employees 100